RLMD.US Relmada Therapeutics Inc

Healthcare Pharmaceuticals USA Stocks
3.54 USD
Close of Nov 17, 2026
2.98 8.00
Market cap
USD 378M
P/E
-
P/B
2.18x
ROE
-31.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is RLMD.US undervalued?

Graham number

The Graham number of Relmada Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Relmada Therapeutics Inc fundamental analysis

No fundamental analysis for Relmada Therapeutics Inc yet.

Relmada Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Relmada Therapeutics Inc

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, touret…

Full company profile